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Abstract
Background:  Peripheral blood is an accessible and informative source of transcriptomal
information for many human disease and pharmacogenomic studies. While there can be significant
advantages to analyzing RNA isolated from whole blood, particularly in clinical studies, the
preparation of samples for microarray analysis is complicated by the need to minimize artifacts
associated with highly abundant globin RNA transcripts. The impact of globin RNA transcripts on
expression profiling data can potentially be reduced by using RNA preparation and labeling
methods that remove or block globin RNA during the microarray assay. We compared four
different methods for preparing microarray hybridization targets from human whole blood
collected in PAXGene tubes. Three of the methods utilized the Affymetrix one-cycle cDNA
synthesis/in vitro transcription protocol but varied treatment of input RNA as follows: i. no
treatment; ii. treatment with GLOBINclear; or iii. treatment with globin PNA oligos. In the fourth
method cDNA targets were prepared with the Ovation amplification and labeling system.
Results: We find that microarray targets generated with labeling methods that reduce globin
mRNA levels or minimize the impact of globin transcripts during hybridization detect more
transcripts in the microarray assay compared with the standard Affymetrix method. Comparison
of microarray results with quantitative PCR analysis of a panel of genes from the NF-kappa B
pathway shows good correlation of transcript measurements produced with all four target
preparation methods, although method-specific differences in overall correlation were observed.
The impact of freezing blood collected in PAXGene tubes on data reproducibility was also
examined. Expression profiles show little or no difference when RNA is extracted from either fresh
or frozen blood samples.
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Conclusion: RNA preparation and labeling methods designed to reduce the impact of globin
mRNA transcripts can significantly improve the sensitivity of the DNA microarray expression
profiling assay for whole blood samples. While blockage of globin transcripts during first strand
cDNA synthesis with globin PNAs resulted in the best overall performance in this study, we
conclude that selection of a protocol for expression profiling studies in blood should depend on
several factors, including implementation requirements of the method and study design. RNA
isolated from either freshly collected or frozen blood samples stored in PAXGene tubes can be
used without altering gene expression profiles.
Background
Gene expression profiling of RNA extracted from periph-
eral blood is an informative method used to identify
biomarkers, examine disease states, and investigate
immune responses. However, the relatively high propor-
tion of globin messenger RNA present in total RNA
extracted from whole blood can reduce the efficacy of the
microarray assay by interfering with the detection of less
abundant gene transcripts [1-3]. Furthermore, it has been
observed that, when compared with a leukocyte isolation
protocol, RNA isolated directly from whole blood is asso-
ciated with increased noise and reduced sensitivity in the
gene expression assay [2,4,5] (K. Vartanian, C. Har-
rington, unpublished observations).
Common laboratory practice often includes fractionation
of whole blood components prior to RNA extraction. The
process allows for the removal of the red blood cells from
whole blood isolations and facilitates the study of more
homogeneous cell populations. Depending on the frac-
tionation method selected, partial or complete removal of
reticulocytes, the primary source of globin RNA, may be
achieved. Despite the obstacle posed by globin RNA con-
tamination, however, there are compelling reasons to
study gene expression from whole blood rather than from
subpopulations such as neutrophils. First, to capture
expression profiles that accurately reflect the transcrip-
tome at time of blood collection and to minimize sample
handling artifacts, it is preferable to avoid additional
processing steps as some degree of cell activation is inevi-
table during cell fractionation. Second, even when frac-
tionation steps are performed, α and β globin mRNA
transcripts are often the most abundant transcripts
present in total RNA extracted from leukocyte-enriched
populations [2] and the fractionation itself can contribute
to increases in sample-to-sample variability in the micro-
array assay [5]. Third, there are a myriad of populations
within whole blood: neutrophils, T cells, B cells, NK cells,
monocytes, eosinophils, basophils, dendritic cells, and
subsets for each of the above. While some studies may
require analysis of individual cell types, if all these popu-
lations can be studied together, the cost savings is substan-
tial. Finally, working with whole blood saves time and, if
specimens are being collected at multiple study sites, the
methodology facilitates a uniformity that is diminished
with each additional step in the processing of the blood.
Several commercially available methods for reducing the
impact of globin RNA transcripts in the microarray expres-
sion assay have been developed. One approach involves
the removal of α and β globin RNAs from total RNA by
selective hybridization and magnetic bead separation [6]
prior to amplification and labeling of microarray targets.
The Ambion GLOBINclear kit utilizes this pre-labeling
method of globin transcript depletion. Using a different
approach, Affymetrix and PreAnalytiX have developed a
protocol in which α- and β-globin mRNA mRNAs are
selectively blocked during the cDNA synthesis step of the
microarray target preparation protocol with a mixture of
peptide nucleic acids (PNAs) complementary to globin
transcripts. Recently, a third method has been released by
NuGEN Technologies that does not directly reduce globin
RNA transcripts but rather uses a proprietary technology
to produce a single-stranded cDNA microarray target [7].
The cDNA targets might be less prone to the cross-hybrid-
ization artifacts seen with cRNA targets [8], thus reducing
the impact of highly abundant transcripts present in the
target and increasing assay sensitivity [9].
Each method has been demonstrated to produce array
data in which an increased number of non-globin gene
transcripts are detected [1,10], and Debey et al[11] have
shown that another globin RNA reduction method also
improves microarray performance with whole blood sam-
ples. Currently, however, there is limited information
available directly comparing these methods or examining
the accuracy of microarray profiles generated using the
individual methods. In this study we examine the sensitiv-
ity, reproducibility and concordance of microarray data
produced by targets generated from globin RNA-depleted
and non-depleted total RNA using two different target
labeling methods: the Affymetrix one-cycle target labeling
(standard laboratory method) protocol and the NuGEN
Ovation protocol. Quantitative RT-PCR of total blood
RNA was used to generate an independent measure of
mRNA levels from genes of the human NF-κB signaling
pathway in order to evaluate the accuracy of the microar-
ray results. The results of this study allow us to identifyBMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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optimal methods for preparing microarray targets from
blood RNA for expression analysis. In addition we com-
pare expression profiles of fresh and frozen whole blood
samples collected in PAXGene tubes to assess the impact
freezing may have on expression profiling.
Results and discussion
RNA isolated directly from whole blood and processed
using standard target preparation methods produces gene
expression profiles with increased noise and reduced sen-
sitivity compared with total RNA isolated after various
leukocyte isolation protocols. However, the advantages of
profiling gene expression from whole blood are compel-
ling: 1) cell fractionation steps that may artifactually alter
gene expression patterns are avoided; 2) easy and rapid
isolation of RNA from whole blood facilitates clinical
studies; 3) even rare subpopulations of cells such as den-
dritic cells or eosinophils remain included in the tran-
scriptome; and 4) costs are vastly reduced. To increase
assay sensitivity and reproducibility when profiling RNA
extracted from whole blood, it is necessary to employ a
method to reduce the impact of highly abundant globin
mRNAs on target hybridization with the microarray. In
this study, four methods for RNA preparation and labe-
ling were examined to determine which protocol pro-
duced the most sensitive and reproducible results when
blood RNA isolated from PAXGene tubes was used as
input. In addition, since the option to freeze a whole
blood sample allows samples to be collected over time
and at different study sites prior to processing, the effects
of freezing blood samples were examined by comparing
data generated from both fresh and frozen specimens.
Freezing blood samples after collection has the advantage
of allowing batching of samples for RNA extraction and
simplifying the blood collection protocol for multicenter
studies.
Methods summary
Blood samples were collected from healthy, human
donors in PAXGene tubes; RNA was isolated either on day
of collection or after freezing and storage. Four different
methods of microarray target preparation for whole blood
RNA samples were examined (Figure 1). Three of the
methods used total RNA extracted from whole blood as
the starting sample for mRNA amplification and target
labeling: Affymetrix one-cycle target labeling (Method 1:
no depletion_Affymetrix); Affymetrix one-cycle target
labeling with globin PNAs added during cDNA synthesis
(Method 2: Globin PNAs_Affymetrix); and NuGEN Ova-
tion system v1 (Method 4: no depletion_NuGEN). In the
other method tested, total RNA was treated with Ambion
GLOBINclear to reduce globin transcripts prior to labeling
with the Affymetrix one-cycle labeling protocol (Method
3: GLOBINclear_Affymetrix). The Affymetrix one-cycle
target labeling protocol produces biotin-labeled, ampli-
fied cRNA; the NuGEN protocol produces biotin-labeled,
amplified cDNA targets.
Input RNA and target quality assessment
The quality of total RNA prepared from fresh and frozen
PAXGene tubes and from GLOBINclear-treated RNA was
assessed using standard UV spectrophotometry and by
examining electropherogram images generated with the
Agilent Bioanalyzer. Input RNA was of high quality for
both fresh and frozen samples (average RIN score 8.9 and
8.8, respectively) with a slight reduction in average quality
metrics for GLOBINclear-treated samples (average RIN
score 8.6 and 8.5). Reductions in RIN scores after GLOB-
INclear treatment of whole blood RNA were also observed
by Liu et al. [1]. Each amplified target was assessed for
cRNA or cDNA quality by examining electropherogram
images and for yield using UV spectrophotometry. Results
are summarized in Figure 2. For targets generated with
Method 1 (no depletion_Affymetrix) the traces display a
sharp peak characteristic of highly abundant globin cRNA.
This peak is reduced in cRNA targets produced with Meth-
ods 2 (Globin PNAs_Affymetrix) and 3
(GLOBINclear_Affymetrix). The absence of the globin
RNA-associated peak in targets produced following
GLOBINclear treatment or with globin RNA blockage by
PNA oligos during cDNA synthesis is consistent with the
results reported by Liu et al[1] in their study evaluating
these methods. The Bioanalyzer trace of targets produced
with Method 3 (GLOBINclear_Affymetrix) displays a pat-
tern characteristic of mild RNA degradation (a left-shifted
trace); this may be a result of the extra handling steps
required by the GLOBINclear treatment. The cDNA trace
for Method 4 (no depletion_NuGEN) targets does not
show a discrete peak, suggesting that globin RNA amplifi-
cation may also be reduced with this method.
Using recommended RNA inputs for each method, aver-
age cRNA target yield ranged from 20 μg to 102 μg. The
average yield with Method 1 (no depletion_Affymetrix)
using RNA from either fresh or frozen PAXGene tubes is
typical of yields obtained in our laboratory with this
method. We speculate that the high yields for Method 2
(Globin PNAs_Affymetrix) relative to the other Affymetrix
one-cycle target labeling methods are, at least partially,
the result of the higher input RNA amount (5 μg) required
by the Method 2 protocol. The GLOBINclear-treated RNA
produced the lowest cRNA yields with the Affymetrix one-
cycle labeling protocol, as has been observed previously
with this method [1]. The NuGEN method generated an
average cDNA target yield of 2.8 μg from an RNA input of
30 ng, which is within the reported yield range for this
assay. Target yields for all methods tested in this study
were sufficient for performing microarray analysis.BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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Flow diagram of whole blood methods comparison study Figure 1
Flow diagram of whole blood methods comparison study. A total of 8 PAXGene blood tubes were collected from each 
donor: 4 tubes were processed on day of collection and 4 were frozen for later processing. RNA was isolated and pooled prior 
to microarray target labeling with one of four different methods. Microarray results were compared among methods and with 
quantitative RT-PCR for each donor sample.
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Quality assessment of cRNA and cDNA targets Figure 2
Quality assessment of cRNA and cDNA targets. A representative electropherogram (Bioanalyzer trace) of targets pro-
duced with each labeling method is shown. For each method, target yields for all samples are listed to the right of the trace. 
Values in bold text correspond to the sample profiled in the adjacent electropherogram trace.
Method 1: no depletion_Affymetrix
    Target yield (μg)
Donor  Fresh      Frozen 
A   36.35         40.4 
C  65.75         33.35 
D 85.10  66.55
AVG  62.4           46.8 
 St  dev 24.6           17.5 
Method 2:  Globin PNAs _Affymetrix
    
Donor  Fresh      Frozen 
A  98.25          69.10 
C 129.75 80.40
D  76.90        100.00 
AVG  101.6          83.2 
St dev       26.6          15.6 
Method 3: GLOBINclear_Affymetrix
    
Donor Fresh      Frozen 
A  18.50         22.40 
C 20.30  25.40
D  21.50         14.60 
  AVG  20.1           20.8 
St dev    1.5             5.6        
Method 4: no depletion_NuGEN
Donor Fresh      Frozen 
A  2.04           2.98
C  1.83*          3.57 
D  3.24           3.32 
AVG 2.4             3.3 
St dev  0.8             0.3 BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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Array hybridization performance
Targets produced with each labeling method were hybrid-
ized with the GeneChip Human Focus array. Target
amounts and array processing steps were performed
according to the manufacturers' recommendations for the
labeling method and the array format. Overall perform-
ance in the array assay was examined in three ways: 1)
individual array performance metrics (generated with
MAS 5.0); 2) data visualization for assessment of data dis-
tribution and variation; and 3) correlation of detected
transcripts among targets generated with each method.
Array performance metrics (Table 1) indicate that labeling
Method 2 (Globin PNAs_Affymetrix) produced targets
with the highest transcript detection efficiency (%
present) among the methods tested. The next most sensi-
tive result was seen with Method 3
(GLOBINclear_Affymetrix). Background levels were simi-
lar among the targets produced with the three methods
utilizing the Affymetrix one-cycle cDNA/IVT labeling pro-
tocol. The laboratory standard method of target prepara-
tion (no depletion_Affymetrix) demonstrates that lowest
transcript detection when used with whole blood RNA.
The NuGEN Ovation labeling method produced lower
Table 1: GeneChip Array performance metrics
Sample Bg % P Mean Signal Actin Intensity Actin 3'/5' Ratio GAPDH Intensity GAPDH 3'/5' Ratio
METHOD 1
A5 4 . 3 48.3% 95.5 751.4 7.6 410.4 5.9
C 50.3 53.1% 123.3 3437.5 1.4 988.1 1.8
D 47.8 52.2% 107.5 3692.0 1.1 1216.7 1.1
A frozen 49.0 51.2% 95.0 2641.6 1.4 1073.3 1.2
C frozen 48.7 54.0% 117.7 3618.0 1.2 1324.7 1.2
D frozen 49.7 51.3% 98.6 2933.7 1.1 1005.6 1.5
Average* 50.1 52.4% 106.3 2845.7 1.2 1003.1 1.4
METHOD 2
A 58.2 58.9% 270.4 8145.6 1.5 3492.0 0.9
C 52.7 58.7% 220.0 6812.9 1.5 2742.4 1.0
D 62.2 55.9% 179.7 6953.0 1.1 2697.9 1.0
A frozen 53.1 57.2% 177.2 5616.2 1.5 2336.8 1.1
C frozen 56.1 58.5% 195.4 6458.0 1.2 2580.7 0.9
D frozen 55.2 58.3% 196.8 6952.1 1.2 3016.1 1.0
Average 56.2 57.9% 206.6 6823.0 1.3 2811.0 1.0
METHOD 3
A 53.2 56.9% 155.8 2014.2 3.2 680.1 8.3
C 51.3 56.1% 145.1 4514.5 1.1 689.9 4.3
D 51.7 55.7% 144.5 3492.7 1.7 676.4 8.0
A frozen 46.5 56.6% 136.7 3400.5 2.0 1442.0 1.4
C frozen 49.5 55.1% 129.7 1491.0 3.9 583.8 8.9
D frozen 45.6 56.3% 132.2 3598.3 1.2 678.7 2.9
Average 49.6 56.1% 140.7 3085.2 2.2 791.8 5.6
METHOD 4
A 41.8 55.8% 97.0 2057.3 7.2 301.5 1.5
C 30.9 53.4% 63.6 1658.4 10.7 161.3 1.6
D 31.2 55.7% 82.4 2039.6 10.2 259.4 1.9
A frozen 30.8 53.8% 65.2 1577.0 15.5 183.4 2.9
C frozen 34.8 53.3% 73.2 1753.5 11.1 190.2 2.1
D frozen 37.9 53.3% 79.3 1838.4 10.6 256.3 1.8
Average 34.6 54.2% 76.8 1820.7 10.9 225.4 2.0
Microarray targets prepared from donors A, C, and D were hybridized to the GeneChip Human Focus Array. Overall performance values 
determined with unscaled MAS 5.0 analysis of each array are listed. Bold font indicates metric values that fall below empirical quality control 
standards established in our laboratory. All arrays passed post-hybridization visual inspection. *Average values for Method 1 do not include sample A 
which was flagged as a low performance outlier.BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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overall signal and lower background on the arrays. Actin
3'/5' ratios measured with this method are 5–9 fold higher
than with the other labeling methods. This pattern is con-
sistent with previous reports describing the Ovation sys-
tem [7,12] and, taken together with the low GAPDH ratios
produced with this Method, is not likely to represent poor
quality RNA or targets. Only one microarray assay was
flagged for poor performance in this study: Sample A,
Method 1 (no depletion_Affymetrix). (In our estimation,
the performance characteristics of Sample A with Method
1 indicate a technical outlier whose underperformance is
not a result of sample source or labeling method type.)
Examination of probe cell intensity distributions prior to
normalization shows that overall signal distribution pat-
terns (Figure 3A) varied with the labeling method.
Within-method variation is low across methods, with the
exception of Method 4 (no depletion_NuGEN) which
showed somewhat greater variation than the other meth-
ods. Probe cell intensity range, however, is notably differ-
ent among methods, with Method 2 (Globin
PNAs_Affymetrix) showing the greatest range and Method
4 (no depletion_NuGEN) the lowest. Because of the large
differences in detection sensitivity and gene expression
patterns among the four labeling methods, likely due to
differences in globin transcript levels and target nucleic
acid types (i.e., cRNA vs cDNA), we applied model-based
normalization algorithms to within-method array data as
well as across the entire data set. Following gene summa-
rization and MAS scaling (Figure 3B) or RMA quantile
normalization (Figure 3C–F), within-method variation is
not pronounced for any of the labeling methods,
although, Method 1(no depletion_Affymetrix) showed a
compressed probe set signal intensity range compared to
the other labeling methods. Interestingly, in this study,
the sample-to-sample variation observed with Method 1
(no depletion_Affymetrix) is reduced compared with
other microarray studies in our laboratory using this
method with RNA extracted from whole blood or Ficoll-
Hypaque-isolated PBMCs. Possible explanations for the
reduced variation in the present study include 1) use of
highly standardized blood collection and RNA processing
protocols, with all target labeling performed in a single
batch, 2) low number of independent samples in this
study is insufficient to detect typical variation, 3) blood
samples were only collected from healthy donors. This lat-
ter possibility is consistent with the report of Whitney et
al [13] in which a reduced variation in gene expression
patterns in blood from healthy individuals compared to
patients with bacterial infection was observed.
Sample-to-sample variation was also examined by meas-
uring similarity among expression profiles from different
donor samples processed with the same target preparation
method. A high within-method correlation (average r =
0.98) was measured for Methods 1 (no
depletion_Affymetrix; excluding the Sample A outlier), 2
(Globin PNAs_Affymetrix) and 4 (no
depletion_NuGEN). Method 3
(GLOBINclear_Affymetrix) again showed somewhat
poorer performance (average r = 0.96).
Comparison of globin transcript detection
We assessed the extent of globin transcript depletion in
the microarray assay with each labeling method by exam-
ining α- and β-globin mRNA signal intensities normalized
to actin mRNA signal. All of the globin mRNA depletion
methods resulted in decreased α- and β-globin mRNA
transcript measurements relative to Method 1 (no
depletion_Affymetrix) targets. Method 2 (Globin
PNAs_Affymetrix) generated targets that showed the
greatest reduction in globin mRNAs (Figure 4). Interest-
ingly, Methods 2 (Globin PNAs_Affymetrix) and 4 (no
depletion_NuGEN) also resulted in reduced hybridiza-
tion signal with γ globin mRNA probe sets on the Affyme-
trix arrays, but Method 3 (GLOBINclear_Affymetrix)
showed no reduction in these signals relative to the stand-
ard Method 1 (no depletion_Affymetrix) results.
Quantitative RT-PCR validation
Expression levels of a panel of 84 genes from the NF-κB
pathway plus 5 housekeeping genes were measured by
quantitative RT-PCR using total RNA from two of the indi-
viduals profiled in the microarray component of this
study. The NF-κB pathway was chosen because of biolog-
ical interest to study authors and high overlap of panel
genes with genes represented on the Human Focus array.
RNA prepared from both frozen and unfrozen PaxGene
tubes was analyzed for each donor. All of the genes meas-
ured in the RT-PCR assay were scored as present in the
microarray profiles produced with targets from one or
more of the methods examined in this study.
Comparison of the RT-PCR data with array profiles for 75
matched genes demonstrated that Method 2 (Globin
PNAs_Affymetrix) produced expression data that most
closely correlates with the RT-PCR results, with an average
Pearson correlation of 0.77 (Figure 5 and Table 2). Sur-
prisingly, despite the presence of abundant levels of
globin transcripts, the targets produced by the one-cycle
cDNA synthesis protocol with Affymetrix IVT (no
depletion_Affymetrix), show the next highest correlation
with the RT-PCR results. In their comparison of differen-
tial gene expression results, Barker et al [8] reported that
cDNA targets prepared with the Ovation v1 method more
closely tracked with quantitative RT-PCR measurements
than cRNA targets prepared with the traditional one-cycle
cDNA/IVT method (Method 1 in the present study). It is
difficult to interpret the significance of this observation in
the context of our results as RNA source, study design,BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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Box plots of raw probe cell and normalized probe set signal intensities Figure 3
Box plots of raw probe cell and normalized probe set signal intensities. All box plots were generated with Affymetrix 
Expression Console. A. Probe cell intensity box plot generated from CEL file probe cell intensity values for all targets; B. Box 
plot of globally scaled, MAS 5.0 summarized probe set signals for all targets. C. Box plot of RMA summarized probe set signals 
for Method 1 targets; D. Box plot of RMA summarized probe set signals for Method 2 targets; E. Box plot of RMA summarized 
probe set signals for Method 3 targets; F. Box plot of RMA summarized probe set signals for Method 4 targets. Donor source 
is indicated on the X-axis: red text indicates RNA isolation from PAXGene tubes on the day of collection, blue text indicates 
RNA isolation from PAXGene tube following freezing.BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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PCR primer selection rationale, and analysis methodol-
ogy differ significantly between the two studies. However,
taken together, the results may indicate that absolute
measurements of gene expression and relative measure-
ments of differential gene expression may not be co-ordi-
nately affected by a particular target preparation method.
Cross-method comparison of expression profiles
Differences among transcriptome profiles generated with
each method were examined to assess concordance
among methods. Transcriptome patterns were identified
for each labeling method by filtering for probe sets with a
minimum detection p-value of 0.05 in at least 4 of the 6
within-method array assays using gene level expression
data generated with MAS 5.0. Overlap among these tran-
script lists for Method 2 (Globin PNAs_Affymetrix),
Method 3 (GLOBINclear_Affymetrix) and Method 4 (no
depletion_NuGEN) is illustrated in the Venn diagram in
Figure 6. By far, the majority of transcripts detected with
any one method were also detected by each of the other
Relative signal levels for globin transcripts in microarray data Figure 4
Relative signal levels for globin transcripts in microarray data. The average log2 intensity ratio of globin RNA probe 
sets to the control actin probe set is shown. The Human Genome Focus Array contains two probe sets that hybridize with γ 
hemoglobin RNA, two probe sets that hybridize with α-globin RNA, and one probe set that hybridizes with β-globin RNA.
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Table 2: Correlation (r) of quantitative RT-PCR and microarray data for each Method
Donor Method 1
No depletion_Affy
Method 2
Globin PNAs_Affy
Method 3
GLOBINclear_Affy
Method 4
No depletion_NuGEN
C -0.72 -0.77 -0.70 -0.71
D -0.75 -0.76 -0.69 -0.70
C frozen -0.77 -0.77 -0.73 -0.71
D frozen -0.75 -0.78 -0.69 -0.70
Correlation of RT-PCR and microarray expression measurements for 75 genes of the NF-κB pathway is shown: ΔC(t) values for RT-PCR and 
scaled, MAS 5.0 gene level signals for microarray data. The Pearson product moment correlation coefficient is reported for each target-labeling 
method examined in this study. RNA samples from donors C and D were prepared from either fresh or frozen PAXGene tubes.BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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globin-signal reduction methods (4015 probe sets; 46%
of total, non-control probe sets on the Human Genome
Focus Array). However, over 700 probe sets were only
detected with two of the methods and both Methods 2
(Globin PNAs_Affymetrix) and 4 (no depletion_NuGEN)
uniquely detected a few hundred additional transcripts.
Most transcripts detected with Method 1 (no
depletion_Affymetrix) were included in the set of tran-
scripts detected with Method 2 (Globin PNAs_Affymetrix)
(98.6%); only 40 probe sets met the detection filtering cri-
teria exclusively in Method 1 (no depletion_Affymetrix)
samples, all of which were associated with low probe set
signal intensities. It is likely that at least some of the low
signal probe sets scored as present with a single target
preparation method represent false positives or low abun-
dance transcripts at the borderline for detection. Only
Method 4 (no depletion_NuGEN) had a significant por-
tion of uniquely detected transcripts with probe set signal
intensities above the lowest quartile of detected transcript
intensities.
Comparison of microarray and quantitative RT-PCR results for genes of NF-κB pathway Figure 5
Comparison of microarray and quantitative RT-PCR results for genes of NF-κB pathway. Scatter plots of MAS5.0 
scaled probe set intensities measured on the GeneChip Human Genome Focus Array and real-time PCR ΔCt values for 75 
genes of the NF-κB pathway. A. Sample C, microarray targets prepared with Method 1; B. Sample C, microarray targets pre-
pared with Method 2; C. Sample C, microarray targets prepared with Method 3; D. Sample C, microarray targets prepared 
with Method 4. Microarray data was analyzed and scaled with MAS 5.0 and RT-PCR data was normalized by subtracting the 
mean Ct value for five housekeeping genes (β2-microglobin, hypoxanthine phosphoribosyltransferase 1, ribosomal protein 
L13a, glyceraldehyde-3-phosphate dehydrogenase, and β-actin) to yield ΔCt values. Pearson correlation coefficients are 
reported for each comparison.BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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Overall, the vast majority of gene transcripts detected with
each method were also detected by the other three meth-
ods. The highest expression concordance was observed
between Methods 1 (no depletion_Affymetrix) and 2
(Globin PNAs_Affymetrix). The Globin PNAs_Affymetrix
method and the no depletion_NuGEN method each
detect a significant number of gene transcripts (~3% of all
transcripts represented on the Human Genome Focus
array) not detected by any of the other methods tested in
this study. Four of the transcripts detected with only one
labeling method (3 in no depletion_NuGEN and 1 one in
Globin PNAs_Affymetrix) correspond to genes whose
transcription was confirmed in the quantitative RT-PCR
analysis. This observation suggests that both the no
depletion_NuGEN and the Globin PNAs_Affymetrix
method produce microarray data that accurately measures
gene expression not detected by the other methods.
Impact of freezing whole blood in PAXGene tubes
Microarry performance of RNA extracted from blood col-
lected in PAXGene tubes immediately following a 2 hr
room temperature incubation or after a 2 hr incubation
and freezing at -80°C was compared. Correlation between
array data from fresh and frozen PAXGene preparations
from each donor was high across all samples prepared
with Methods 1 (no depletion_Affymetrix), 2 (Globin
PNAs_Affymetrix) or 4 (no depletion_NuGEN), with the
exception of donor A using Method 1, where one of the
microarray assays underperformed (Table 3). Method 3
(Globin PNAs_Affymetrix) resulted in fresh and frozen
sample correlations that were somewhat reduced com-
pared to the other target labeling methods. Comparison
of the quantitative PCR results of fresh and frozen blood
preparations from donors C and D demonstrated a simi-
lar high level of correlation (r = 0.98 for donor C and 0.99
for donor B).
Our results indicate that freezing blood collected in PAX-
Gene tubes prior to RNA extraction has little impact on
the RNA profiles measured in the microarray assay. This
observation is consistent with the report of Ovstebo et
al[14] in which the expression profile of 11 mRNAs
assessed with RT-PCR analysis was not altered by freezing
PAXGene tubes prior to RNA extraction.
Microarray assay reproducibility
Given the overall similarity in fresh and frozen sample
pairs as measured in both the microarray and RT-PCR
analyses, we elected to use the fresh/frozen pairs for each
donor to examine array assay reproducibility among the
different assay methods. Method 2 (Globin
PNAs_Affymetrix) showed the highest reproducibility in
paired donor samples (average r = 0.99). Reproducibility
was also high with Methods 1 (no depletion_Affymetrix)
and 4 (no depletion_NuGEN) (average r = 0.98), but
slightly reduced with Method 3
(GLOBINclear_Affymetrix) (average r = 0.97).
Venn diagram of transcript detection among globin RNA  reduction methods Figure 6
Venn diagram of transcript detection among globin 
RNA reduction methods. Gene expression lists for each 
target preparation method were determined by filtering for 
all probe sets scored as Present (p-value < 0.05) in 4 out of 6 
microarray assays (donors A, C and D). Overlap of detected 
transcripts is shown for Method 2 (Globin 
PNAs_Affymetrix), Method 3 (GLOBINclear_Affymetrix) 
and Method 4 (no depletion_NuGEN).
Table 3: Correlation (r) of array data from donor RNA extracted from fresh versus frozen PAXgene tubes
Donor Method 1
No depletion_Affy
Method 2
Globin PNAs_Affy
Method 3
GLOBINclear_Affy
Method 4
No depletion_NuGEN
A 0.953 0.991 0.959 0.979
C 0.989 0.993 0.959 0.981
D 0.996 0.992 0.988 0.993
Pearson correlation coefficients for each within-method comparison are reported. Microarray data was analyzed and scaled with MAS 5.0.BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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Conclusion
Removing globin transcripts from cRNA hybridization
targets prepared from whole blood samples results in
increased sensitivity in microarray expression profiles.
Sensitivity is also increased when cDNA hybridization tar-
gets prepared from undepleted RNA are used instead of
cRNA targets. All of the methods tested in this study gen-
erate highly reproducible data, except when total RNA is
pre-treated to remove globin transcripts
(GLOBINclear_Affymetrix method). Comparison of
microarray gene level signals with real-time PCR data sug-
gests that the Globin PNAs_Affymetrix method produces
the most accurate microarray results, although, all meth-
ods produce data that correlate well with the RT-PCR
measurements. Performance results for each method are
summarized in Table 4.
Before selecting a protocol for use in an expression profil-
ing study of whole blood, however, several factors must
be considered.
Method 1, Affymetrix one-cycle target labeling protocol 
with no globin RNA depletion produces reliable data but 
sensitivity is low
Advantages
This method required relatively low RNA amounts and
did not require any additional processing steps. Overall,
correlation to real-time PCR data was second only to the
Globin PNAs_Affymetrix method (Method 2).
Considerations
It has been well reported that performing microarray pro-
filing of RNA extracted from whole blood using this
method without modification results in less sensitive data
with high levels of sample-to-sample variability
[2,4,5,11]. In the present study the use of this method
with whole blood samples resulted in the lowest tran-
script detection of all the methods tested.
Method 2, Affymetrix one-cycle target labeling protocol 
with globin PNAs generates sensitive and reproducible 
results
Advantages
Sensitivity was highest with this method. Additionally,
this method also produced the lowest relative α- and β-
globin intensities when the signal was normalized to a
housekeeping control gene, further confirming the effec-
tiveness of the reduction. Among all protocols tested in
this study, the globin PNAs method demonstrated the
highest reproducibility when correlation values were
measured between donor replicates. Finally, microarray
RNA expression values produced with the PNA method
showed the highest correlation to RT-PCR measurements
of a selected gene panel in the same RNA samples com-
pared to all other methods.
Considerations
While targets prepared following the PNA method pro-
duced the best overall results in the microarray assay,
before selecting this protocol to profile expression pat-
terns of whole blood, it is important to note that, among
the protocols examined in this paper, the PNA method is
one of the more time-consuming and requires the highest
amount of total RNA. Although recent studies in our lab-
oratory show that the PNA method can be successfully
applied with RNA inputs as low as 2 μg (unpublished
data), the relatively high RNA amounts required by this
method could be a confounding factor if the amount of
RNA available for expression profiling is low. Further-
more, the PNA sequences supported by Affymetrix for use
in this protocol are designed to bind to human α- and β-
globin transcripts. Consequently if blood RNA extracted
from non-human species is to be analyzed, it would be
Table 4: Summary of Methods performance
METHOD Overall Performance Assessment
Method 1 – Affymetrix one-cycle target labeling of  Lowest sensitivity
whole blood RNA (no depletion_Affymetrix) Good reproducibility
Good target integrity
Method 2 – Affymetrix one-cycle target labeling of High sensitivity
whole blood RNA with globin PNAs during cDNA  High reproducibility
synthesis (Globin PNAs_Affymetrix) Good target integrity
Method 3 – Affymetrix one-cycle labeling of whole High sensitivity
blood RNA treated with Ambion GLOBINclear Lowest reproducibility
(GLOBINclear_Affymetrix) Marginal target integrity
Method 4 – NuGEN Ovation v1 amplification and Moderate sensitivity
labeling of whole blood RNA (no depletion_NuGEN) High reproducibility
Good target integrityBMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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necessary to design and optimize peptide nucleic acid
sequences for the species of interest. Also note that PNA
sequences recommended by Affymetrix are no longer sold
by Applied Biosystems. The product is now available
through Panagene (Yuseong, Daejeon, Korea).
Method 3, Ambion GLOBINclear processing prior to 
Affymetrix one-cycle target labeling produces sensitive 
results but is less reproducible in comparison to the other 
methods
Advantages
The third method examined in this study uses a magnetic-
bead based hybridization system to extract globin RNA
from whole blood total RNA prior to amplification. Beads
can be purchased to bind to species-specific globin tran-
scripts (human and rodent), allowing for increased flexi-
bility. Sensitivity is almost as high as that achieved with
the PNA method. Globin probe set intensities, compared
to the housekeeping controls, were reduced but not to the
level observed when using the PNA method.
Considerations
Reproducibility of GLOBINclear targets is lowest of the
methods examined. Furthermore, we noted an increase in
the ratio of 3' versus 5' housekeeping control probe set
intensity, suggesting a slight decrease in the quality of the
target prepared using this method. This trend can likely be
explained by the increased sample handling required to
process the RNA during the bead hybridization and mag-
netic purification steps. Input requirements are also rela-
tively high for this method, again presenting challenges
when sample amounts are limiting. In addition, compar-
ison of microarray expression values generated with this
method showed the lowest correlation with the RT-PCR
results on the NF-κB pathway genes.
Method 4, NuGEN Ovation v1 protocol produces 
somewhat reduced sensitivity measures compared to 
globin RNA depletion methods but reproducibility is high
Advantages
Among the four protocols tested, this labeling protocol
requires the lowest amount of total RNA (5–100 ng) and
does not have a separate globin RNA reduction step.
Instead, the hybridization kinetics of the cDNA target
appear to be less affected than cRNA targets by the abun-
dant globin RNA present in whole blood extractions. The
α- and β-globin RNA intensity measurements in these tar-
gets, compared to a housekeeping control, ranked second
to the PNA method indicating a reduction in globin tran-
script signal compared to the standard labeling method
with no globin RNA depletion. In addition, because a sep-
arate species-specific globin reduction step is not required,
the Ovation method is the most flexible cross-species pro-
tocol of the alternative methods tested.
Considerations
Microarray expression values generated with this method
do not correlate as well with RT-PCR measurements as the
Globin PNAs or standard Affymetrix method. In addition,
detection sensitivity of targets prepared following the
NuGEN Ovation Biotin RNA Amplification and Labeling
System v1 protocol is the lowest of the alternative meth-
ods tested. However, since we completed this study,
NuGEN has released a modified protocol (NuGEN Ova-
tion Whole Blood Labeling System with FLv2) specifically
aimed at minimizing the impact of globin transcripts
when expression profiling RNA extracted from whole
blood. Results from a blood profiling study that used tar-
gets generated with the Whole Blood Ovation System
show significantly increased transcript detection rates
compared to version 1 of this kit (K. Vartanian, R. Slottke,
and C. Harrington, unpublished data). It is likely that the
Ovation Whole Blood FLv2 system retains the high repro-
ducibility and implementation advantages of the version
1 system while producing microarray data with detection
sensitivity similar to the globin PNAs method. In a study
of small sample protocols for microarray analysis using
non-blood tissues, another aspect of sensitivity, detection
of differential expression between samples, was shown to
be highest with the Ovation method compared to other
small sample protocols and the standard Affymetrix one-
cycle labeling method [15].
Our results and observations can be summarized in five
main points: (1) protocols designed to minimize the
impact of globin transcripts can significantly improve the
performance of whole blood-extracted RNA in an expres-
sion profiling microarray study; (2) methods to reduce
globin RNA prior to target synthesis may require amounts
of RNA that are not feasible in some studies; (3) for non-
human studies, the requirement for species-specific oligo-
nucleotides in globin RNA depletion protocols may limit
use; (4) target preparation protocols can be a major source
of variability; (5) if precautions are taken to properly sta-
bilize extracted blood, the impact of freezing specimens
prior to RNA extraction is minimal.
Methods
Blood collection and RNA isolation
Unfractionated whole blood collection and RNA isolation
were performed using the PAXgene Blood RNA Isolation
System (PreAnalytiX, a Qiagen BD Company, Valencia,
CA, USA). PaxGene tubes contain a proprietary reagent to
reduce intracellular RNA degradation and minimize
induction of gene expression [16]. With the approval of
the OHSU Institutional Review Board, blood was col-
lected from four healthy donors using eight PAXGene
tubes per individual. After incubation for two hours at
room temperature, four PAXGene tubes per donor were
transferred to a -80°C freezer. RNA was isolated from theBMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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remaining tubes on the day of collection and from the fro-
zen tubes after storage at -80°C for at least one week.
DNase-treatment was performed as per PAXGene manu-
facturer's recommendation. After pooling samples from 4
frozen or 4 fresh PAXGene tubes for each donor, RNA
recovery and quality were assessed by examining UV 260/
280 absorbance ratios and RNA size distribution on RNA
Nano LabChips (Agilent Technologies, Santa Clara, CA,
USA) processed on the Agilent 2100 Bioanalyzer. An RNA
Integrity Number (RIN) was generated for each Bioana-
lyzer trace using Expert software (Agilent). For inclusion
in this study, a minimum of 12 μg of RNA per donor from
both fresh and frozen blood preparations were required in
order to have sufficient material for RNA quality assess-
ments and manufacturer recommended inputs for each
labeling protocol. Samples from three of the four donors
met the quantitative and qualitative criteria.
Target preparation methods overview
Amplifications and labeling were performed for each
donor using one of the following four methods with RNA
extracted from fresh and frozen blood samples: Method 1
– Affymetrix one-cycle cDNA synthesis/Affymetrix in
vitro-transcription (IVT) on whole blood RNA (no
depletion_Affymetrix); Method 2 – Affymetrix one-cycle
cDNA/Affymetrix IVT with globin peptide nucleic acids
(PNAs) inclusion during cDNA synthesis (Globin
PNAs_Affymetrix); and Method 3-RNA pre-treated with
Ambion GLOBINclear beads to reduce globin transcripts
prior to labeling with the Affymetrix one-cycle cDNA syn-
thesis/Affymetrix IVT (GLOBINclear_ Affymetrix). In the
fourth method tested, cDNA target was synthesized from
whole blood RNA using the NuGEN Ovation Biotin RNA
Amplification and Labeling System v1 (no
depletion_NuGEN). Total RNA input amounts were
based on manufacturer's recommendations for each
method.
Method 1: Affymetrix one-cycle cDNA synthesis/
Affymetrix IVT (no depletion_Affymetrix)
Method 1 employed the standard laboratory method for
amplification and labeling of total RNA. Target synthesis
was performed following the Affymetrix GeneChip
Expression Analysis Technical Manual, rev. 5 http://
www.affymetrix.com/support/technical/manual/
expression_manual.affx with minor modification. Using
1 μg of total RNA as input, messenger RNA was amplified
and labeled in two steps. In the first step, mRNA was con-
verted to double-stranded cDNA and purified by phenol-
chloroform-isoamyl alcohol extraction and ethanol pre-
cipitation. In the second step, amplified and biotinylated
cRNA (the target) was produced by in vitro transcription
(IVT). Unincorporated nucleotides were removed using
the RNeasy Mini kit (Qiagen) followed by an ethanol pre-
cipitation of the labeled target.
Method 2: Affymetrix one-cycle cDNA synthesis/
Affymetrix IVT with PNA treatment of total RNA (Globin 
PNAs_Affymetrix)
The standard Affymetrix amplification and labeling was
performed with the following modification: four peptide
nucleic acid (PNA) oligonucleotides (Applied Biosystems,
Foster City, CA, USA) designed to anneal to human α- and
β-globin mRNA were added to the total RNA preparations
immediately prior to initiation of the target synthesis step
in order to bind globin mRNA and block cDNA synthesis.
The PNA oligonucleotide stocks were prepared on day of
use at concentrations recommended by Affymetrix
http:www.affymetrix.com/support/technical/byprod
uct.affx?product=bloodrna. Globin reduction PNA master
mix was prepared by adding equal amounts of the globin
PNA stocks. Five μg of total RNA were incubated with
oligo-dT primer and 1 μl PNA master mix for 10 minutes
at 70°C prior to first strand cDNA synthesis; all subse-
quent steps for target amplification and labeling were as
described for Method 1.
Method 3: Affymetrix one-cycle cDNA synthesis/
Affymetrix IVT with GLOBINclear treated total RNA 
(GLOBINclear_Affymetrix)
Globin mRNA depletion was performed in three steps
using the GLOBINclear Kit (Ambion, Austin, TX, USA).
First, species-specific biotinylated oligonucleotides com-
plementary to human α- and β-globin mRNA were
hybridized with total RNA (5 μg). Second, magnetic
streptavidin-coated beads were added to bind the bioti-
nylated-oligonucleotide:globin RNA complexes. Finally, a
magnet was used to remove beads with the selectively
bound α- and β-globin transcripts. After globin mRNA
depletion, RNA quantity was determined by UV absorb-
ance and RNA integrity was assessed using RNA Nano
LabChips as described above. RNA recovery following
GLOBINclear treatment ranged from 2–5 μg. Target labe-
ling and amplification steps were then performed as
described for Method 1.
Method 4: NuGEN Ovation Biotin RNA Amplification and 
Labeling System v.1 (no depletion_NuGEN)
Ovation v1 labeling and amplification reagents were
obtained from NuGEN Technologies, Inc (San Carlos, CA,
USA) and biotinylated cDNA targets were prepared
according to manufacturer's instructions. Double-
stranded cDNA was synthesized from 30 ng total RNA,
followed by a linear isothermal amplification (SPIA
Amplification™) to produce single-stranded cDNA (tar-
get). A proprietary fragmentation and direct labeling proc-
ess attached biotin to the amplified target. Target
purifications were performed using DNA Clean and Con-
centrator – 25 (Zymo Research, Orange, CA, USA) and the
DyeEx 2.0 Spin Kit (Qiagen).BMC Genomics 2009, 10:2 http://www.biomedcentral.com/1471-2164/10/2
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Array hybridization and processing
Targets labeled with Affymetrix one-cycle cDNA synthesis/
Affymetrix IVT (Methods 1, 2 and 3) were chemically frag-
mented as per Affymetrix's recommendations and com-
bined with Affymetrix biotinylated hybridization controls
(oligomer B2 and cRNAs for BioB, BioC, BioD and CreX)
in hybridization buffer. Hybridizations were performed
for 16 hours at 45°C after addition of 6.5 μg of target to
the GeneChip Human Genome Focus array (Affymetrix),
containing 8700 probe sets. Post-hybridization array
processing was performed according to manufacturer's
recommendations. The distribution of fluorescent mate-
rial on the processed array was determined using the
Affymetrix 3000 GeneArray laser scanner with the 7G
upgrade. Image inspection was performed manually
immediately following each scan.
For targets labeled with NuGEN Ovation system (Method
4), the hybridization and processing outlined above was
performed with the following modification: following
NuGEN's recommendations, 1.3 μg of cDNA target were
mixed with Affymetrix hybridization controls in hybridi-
zation buffer and hybridized with the Human Genome
Focus array for 18 hours at 45°C.
Microarray data quality assessment
The array image scan was processed with Affymetrix
Microarray Suite, version 5.0, (MAS 5.0) software. Gene-
Chip expression Arrays contain control probe sets for both
spiked and endogenous RNA transcripts (e.g., BioB, BioC,
BioD, CreX and species-specific actin and GAPDH). Fol-
lowing absolute analysis of the array pattern with MAS, six
values were examined to assess overall assay performance:
background, noise, average Signal, % Present, ratio of Sig-
nal values for probe sets representing the 5' and 3' ends of
actin and GAPDH transcripts, and total Signal for probe
sets for BioB, BioC, BioD and CreX. Assays demonstrating
poor or marginal performance were flagged.
Quantitative RT-PCR
Quantitative RT-PCR was performed on RNA from donors
C and D. cDNA was prepared from selected RNA samples
(1 μg each) with a RT2 PCR Array First Strand Kit (Super-
Array Bioscience, Frederick, MD, USA) following the man-
ufacturer's instructions. The product was combined with
SuperArray PCR SYBR Green master mix and pipetted into
all wells of a 96-well RT2Profiler™ PCR Array for the
human NF-κB pathway (SuperArray APHS-025A) per the
manufacturer's instructions. After 10 min at 95°C to acti-
vate the HotStart DNA polymerase, the samples were sub-
jected to 40 cycles of 15 seconds 95°C, 35 seconds at
55°C during which time the SYBR Green fluorescence was
recorded, and 30 seconds at 72°C with a Chromo4 ther-
mocycler (BioRad Laboratories, Hercules, CA, USA). Cycle
threshold (Ct) values were obtained for each sample and
were normalized for each plate by subtracting the mean Ct
value for five housekeeping genes (β2-microglobin,
hypoxanthine phosphoribosyltransferase 1, ribosomal
protein L13a, glyceraldehyde-3-phosphate dehydroge-
nase, and β-actin) to yield ΔCt values.
For comparison of RT-PCR results with the microarray
data, 75 genes from the SuperArray NF-κB pathway panel
were matched to probe sets on the Affymetrix Human
Genome Focus array.
Data analysis and visualization
Low-level analysis (background correction, normaliza-
tion, and gene summarization) of microarray data was
performed with both Microarray Suite 5.0 (MAS 5.0)
[17,18] and Robust Multi-Array Average (RMA) [19,20].
Individual arrays were analyzed and scaled with MAS 5.0
using manufacturer's default thresholds for detection
calls. For RMA analysis, arrays were normalized together
and in groups based on target labeling method using RMA
implemented in Affymetrix Expression Console. All
microarray data have been deposited in Gene Expression
Omnibus (GEO) under accession # GSE13292.
Exploratory data analysis was performed on probe cell
intensities and summarized probe set signal values. Box
plots of signal distributions were generated with Expres-
sion Console (Affymetrix). Scatter plots and correlation
measurements were performed using Statistica 6.0
(StatSoft, Tulsa, OK, USA). Venn diagrams were generated
using VENNY, an interactive tool for comparing lists with
Venn diagrams [21]
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